HAMDARD J.BİLİCİ A.Sakin A.Kahraman S.YASİN A. İ.KALACI E.Gokmen I.AÇIKGÖZ Ö.KUTLU Y.Sendur M. A. N.et al.2024-06-252024-06-252024-05-21HAMDARD J., BİLİCİ A., Sakin A., Kahraman S., YASİN A. İ., KALACI E., Gokmen I., AÇIKGÖZ Ö., KUTLU Y., Sendur M. A. N., et al., "Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience", JOURNAL OF CHEMOTHERAPY, 20241120-009Xhttps://hdl.handle.net/20.500.12645/39410We evaluated the incidence, clinicopathological features, prognostic factors, progression-free survival (PFS) and overall survival (OS) of patients with gastric cancer and bone metastases. The medical records of 110 patients with bone metastases were retrospectively analyzed. In our study, the incidence of bone metastases was 3.2%. The median patient age was 60 years. A total of 68 (61.8%) patients exhibited synchronous metastases, and 42 (38.2%) patients developed metachronous metastases. Alkaline phosphatase (ALP) levels were high in 54 (49%) patients. At the median follow-up time of 9.8 months, median PFS and OS times were 4.7 and 6.3 months, respectively. The median interval from the diagnosis to bone metastases was 9.3 months. Univariate analysis showed that Eastern Cooperative Oncology Group Performance Status (ECOG PS) >= 2, stage at diagnosis, time of metastases, number of metastases, presence of extraskeletal metastases, use of zoledronic acid treatment, palliative chemotherapy post-bone metastases and radiotherapy to bone metastases were significant prognostic indicators for PFS. Additionally, ECOG PS >= 2, stage at diagnosis, time of metastases, number of metastases, presence of extraskeletal metastases, zoledronic acid treatment, palliative chemotherapy post-bone metastases, and radiotherapy to bone metastases significantly influenced OS. Moreover, in multivariate analysis, ECOG PS, time of metastases, presence of extra-bone metastases, and the use of palliative chemotherapy after bone metastases were found to be independent prognostic factors for PFS. Moreover, ECOG PS, time of metastases, and use of palliative chemotherapy after bone metastases were significantly independent prognostic indicators for OS. Our findings show that the presence of synchronous metastases, use of palliative chemotherapy, use of zoledronic acid after bone metastases, and ALP level within the normal range were significantly associated with prolonged OS in gastric cancer patients with bone metastases.info:eu-repo/semantics/openAccessTıpDahili Tıp Bilimleriİç HastalıklarıOnkolojiCerrahi Tıp BilimleriPatolojiEczacılıkTemel Eczacılık BilimleriYaşam BilimleriSağlık BilimleriTemel Tıp BilimleriBiyokimyaTemel BilimlerMedicineInternal Medicine SciencesInternal DiseasesOncologySurgery Medicine SciencesPathologyPharmacology and TherapeuticsBasic Pharmaceutics SciencesLife SciencesHealth SciencesFundamental Medical SciencesBiochemistryNatural SciencesONKOLOJİKlinik TıpKlinik Tıp (MED)BULAŞICI HASTALIKLARİmmünolojiYaşam Bilimleri (LIFE)PATOLOJİBiyoloji ve BiyokimyaFARMAKOLOJİ VE ECZACILIKFarmakoloji ve ToksikolojiONCOLOGYCLINICAL MEDICINEClinical Medicine (MED)INFECTIOUS DISEASESIMMUNOLOGYLife Sciences (LIFE)PATHOLOGYBIOLOGY & BIOCHEMISTRYPHARMACOLOGY & PHARMACYPHARMACOLOGY & TOXICOLOGYFarmakolojiFarmakoloji, Toksikoloji ve Eczacılık (çeşitli)Genel Farmakoloji, Toksikoloji ve EczacılıkFarmakoloji (tıbbi)Patoloji ve Adli TıpBulaşıcı hastalıklarHistolojiİlaç RehberleriBiyokimya (tıbbi)Genel İmmünoloji ve MikrobiyolojiPharmacyPharmacologyPharmacology, Toxicology and Pharmaceutics (miscellaneous)General Pharmacology, Toxicology and PharmaceuticsPharmacology (medical)Pathology and Forensic MedicineInfectious DiseasesHistologyDrug GuidesBiochemistry (medical)ImmunologyGeneral Immunology and MicrobiologyarticleWOS:0012337562000018519458915410.1080/1120009x.2024.235845838803194